Active-ingredient Dossier
Montelukast Sodium
Active-ingredient Dossier for Montelukast Sodium (leukotriene receptor antagonist). Australian brands, products, PBS listings, PBAC outcomes — compiled…
- Brand: MONTELUKAST
- Brand: MONTELAIR
- Brand: MONTELUKAST LUPIN
- Brand: MONTELUKAST-WGR
- Brand: SINGULAIR
- Therapeutic area: Respiratory
What is
Montelukast Sodium Montelukast Sodium is a leukotriene receptor antagonist.
Australian brands containing
Montelukast Sodium — MONTELUKAST — SINGULAIR — APO-MONTELUKAST — APX-MONTELUKAST — LUKAFAST — LUKAIR — MONTELAIR — MONTELUKAST LUPIN — MONTELUKAST-WGR — APL-MONTELUKAST TABS
Therapeutic areas
Montelukast Sodium is registered in the respiratory therapeutic area, with 13 brands on the ARTG containing this ingredient.
Sponsor landscape
The ingredient is marketed by six sponsors: Arrotex Pharmaceuticals, Torrent, Organon Pharma, Accord Healthcare, Strides Pharma Science, and Generic Health.
PBS and regulatory activity
One brand containing Montelukast Sodium has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is dated 1 November 2017, and two brands have PBAC outcomes recorded. No AusPARs are on record for this ingredient.